@allogene.com
LEADING THE FUTURE OF CELL THERAPY WITH OUR AlloCAR T™ PLATFORM INNOVATION Multiplex gene-engineering and gene-editing capabilities Proprietary lymphodepletion platform State-of-the-art manufacturing Opportunity for product optimization SEE OUR PIONEERING PLATFORM >> KEY PROGRAMS Cema-cel: Frontline treatment in LBCL Cema-cel: r/r CLL ALLO-316: ccRCC ALLO-329: Autoimmune disease EXPLORE OUR PIPELINE >> LEADERSHIP A highly experienced management team that includes […]
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Allogene Therapeutics is a clinical-stage biotechnology company at the forefront of cancer immunotherapy. With a dedicated focus on developing investigational allogeneic chimeric antigen receptor T cell (AlloCAR T™) products, they aim to revolutionize cancer treatment. Led by a world-class management team with extensive experience in cell therapy, Allogene combines discovery, translational research, development, and cell manufacturing under one roof.
Their goal is to create a pipeline of off-the-shelf CAR T cell candidates, providing readily available cell therapy to more patients with greater speed and reliability. Allogene's innovative approach utilizes gene editing to enhance the efficacy of their CAR T products. While these products are still in the investigational stage and not yet approved by the FDA, they hold great promise as a potentially transformative approach to cancer immunotherapy.
With three locations, five clinical candidates, and thirteen preclinical targets, Allogene is committed to leading the next revolution in cancer treatment
Company Type
Public Company
Company Size
201-500
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online